- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 5 - Value-based Decisions in NSCLC
Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.
Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of “high value, cost-conscious, cost-aware” care. This ensures that only appropriate treatments are administered to patients with cancer.
Dr Sugarbaker suggests to the fellow panelists that the majority of NSCLC patients are not candidates for surgery because they are diagnosed too late for a procedure. Early detection would save a lot of money.
“The issue of imaging and early detection certainly resonates with payers, including myself, and not only economic but ethical considerations,” says Dr Peskin. He adds that while people gravitate toward the terms “targeted” and “precision,” one must verify that those treatments are used by clinicians and oncologists judicially.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More
